caa a22 4500 445808756 CHVBK 20180317145205.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1007/s00415-010-5766-2 doi (NATIONALLICENCE)springer-10.1007/s00415-010-5766-2 A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis [Elektronische Daten] [Howard Zwibel, Gabriel Pardo, Shelly Smith, Douglas Denney, MerriKay Oleen-Burkey] Treatment with disease-modifying immunomodulators is recommended for patients with relapsing-remitting MS (RRMS). However, continuous adherence to treatment with these injected therapies can be challenging. The main objective was to examine the predictors of adherence to glatiramer acetate using a study model derived from Prochaska's transtheoretical model of change. We conducted a 12-week, prospective, observational study. Potential predictors included readiness stage, MS self-efficacy, decisional balance (pros and cons of self-injection), and injection competence. Adults with RRMS, either treatment-naïve (TN) or treatment-experienced (TE), taking glatiramer acetate for the first time were studied. Interventions (including injection training) were implemented to promote adherence. The evaluable population included 146 TN patients and 88 TE patients who had previously discontinued beta-interferons. Adherence rates did not differ between TN and TE groups (86% for both at week 12); however, predictors of adherence did. For TN patients, greater functional self-efficacy, higher self-injection competence at baseline, and improvement in self-injection competence over the first month of therapy predicted adherence. For TE patients, lower body mass index and longer duration of MS predicted adherence. Interventions to improve self-efficacy and self-injection competence should be a priority when treating TN patients. Behavioral predictors of adherence in TE patients warrant further study. Springer-Verlag, 2010 Adherence nationallicence Multiple sclerosis nationallicence Glatiramer acetate nationallicence Self-injection nationallicence Readiness nationallicence Self-efficacy nationallicence Zwibel Howard Neuroscience Consultants, Comprehensive Multiple Sclerosis Center, Coral Gables, FL, USA aut Pardo Gabriel MS Center of Oklahoma, NeuroScience Institute at Mercy, Oklahoma City, OK, USA aut Smith Shelly Commonwealth Pain Specialists (formerly with Neurological Associates, Inc.), Richmond, VA, USA aut Denney Douglas Department of Psychology, University of Kansas, Lawrence, KS, USA aut Oleen-Burkey MerriKay Teva Pharmaceuticals, Medical Affairs, 901 E. 104th Street, Suite 900, 64131, Kansas City, MO, USA aut Journal of Neurology Springer-Verlag 258/3(2011-03-01), 402-411 0340-5354 258:3<402 2011 258 415 https://doi.org/10.1007/s00415-010-5766-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00415-010-5766-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zwibel Howard Neuroscience Consultants, Comprehensive Multiple Sclerosis Center, Coral Gables, FL, USA aut NATIONALLICENCE 700 1- Pardo Gabriel MS Center of Oklahoma, NeuroScience Institute at Mercy, Oklahoma City, OK, USA aut NATIONALLICENCE 700 1- Smith Shelly Commonwealth Pain Specialists (formerly with Neurological Associates, Inc.), Richmond, VA, USA aut NATIONALLICENCE 700 1- Denney Douglas Department of Psychology, University of Kansas, Lawrence, KS, USA aut NATIONALLICENCE 700 1- Oleen-Burkey MerriKay Teva Pharmaceuticals, Medical Affairs, 901 E. 104th Street, Suite 900, 64131, Kansas City, MO, USA aut NATIONALLICENCE 773 0- Journal of Neurology Springer-Verlag 258/3(2011-03-01), 402-411 0340-5354 258:3<402 2011 258 415 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer